Pharmaceuticals
/C O R R E C T I O N -- Informa Markets/
In the news release, "International Healthcare Week Returns to Thailand in 2026 with Expanded Industry Reach", issued on 15 January 2026 by Informa Markets. over PR Newswire, we are advised by the company that the testimonial featured on behalf of i-SENS, South Korea., the name mentioned should ...
2026-01-15 14:17
7584
Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease
SHANGHAI, Jan. 15, 2026 /PRNewswire/ -- AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AB...
2026-01-15 12:11
7598
AIM's Iterative Process High-Efficiency Diploid Rabies Vaccine Completes Phase III Clinical Trials, Efficacy Significantly Higher than Existing Market Products
HONG KONG, Jan. 15, 2026 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 15 that its research and development of the iterative process high-efficiency diploid rabies vaccine has successfully completed the Phase III clinical site work. This marks th...
2026-01-15 08:30
7895
Lynx Analytics Introduces Lumen, an Agentic AI Framework to Improve Decision-Making in Life Sciences
LOS GATOS, Calif., Jan. 14, 2026 /PRNewswire/ -- Lynx Analytics today announced
Lumen
2026-01-14 21:00
4320
Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement to Support Biopharmaceuticals in Global Oncology Program
SEOUL, South Korea, Jan. 14, 2026 /PRNewswire/ -- Rakuten Medical, Inc. and LOTTE Biologics today announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P. Morgan Healthcare Conference in San Francisco to strengthen Rakuten Medical's production capabili...
2026-01-14 07:34
8116
Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis
HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today annou...
2026-01-12 08:00
14563
Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology
CASTRES, France and PARIS, Jan. 9, 2026 /PRNewswire/ -- Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and Robotics on drug discovery, today announced an integrated drug discovery collaboration to identify and develop novel small-molecule drug candidates in ...
2026-01-09 15:00
15905
Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange
HONG KONG, Jan. 9, 2026 /PRNewswire/ -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the cap...
2026-01-09 13:07
22171
Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
MELBOURNE, Australia and INDIANAPOLIS, Jan. 8, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference being held in Sa...
2026-01-08 19:00
14942
Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD
SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced thatChina's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules (Aizhida) f...
2026-01-08 17:58
12537
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Anticipated advancements in weight loss, diabetes, oncology, rare conditions
and protein degraders poised to reshape patient care
LONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT
2026-01-06 16:21
7536
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform
SINGAPORE, Jan. 6, 2026 /PRNewswire/ -- Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical's HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP service...
2026-01-06 12:03
10057
Everest Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced thatIan Woo, President and Chief Fina...
2026-01-06 07:58
13037
Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an internally developed integrin beta-6 (ITGB6)-targeted ant...
2026-01-05 20:00
9546
Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China
Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio HONG KONG, Jan. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the"Group"), a global wellness group off...
2026-01-05 17:36
8096
Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) in combination wi...
2026-01-05 17:29
14748
Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 in participants with diabetes. Enrollment is expected to begin in the first quarter of 2026. -ASC30 demonstrated placebo-...
2026-01-05 08:10
11064
Qiming Venture Partners' Insilico Medicine Successfully Lists on Hong Kong Stock Exchange
SHANGHAI, Dec. 31, 2025 /PRNewswire/ -- Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, today successfully listed on the Hong Kong Stock Exchange (HKEX). The listing marks the largest biotech IPO on theHong Kong stock m...
2025-12-31 08:55
14330
Alphamab Oncology Announces IND Application for a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer was Officially Accepted by CDE
SUZHOU, China, Dec. 29, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immu...
2025-12-29 13:52
5842
Hakka Medicine Goes Global: Jiaying Pharmaceutical Launches the Global Promotion Plan for Hakka Medicine in Hong Kong
HONG KONG, Dec. 24, 2025 /PRNewswire/ -- Recently, Guangdong Jiaying Pharmaceutical Co., Ltd. held the "First Hakka Medicine Historical and Cultural Symposium" and the "Jiaying Hakka Medicine - Double-ingredient Throat Wind Relief Powder Product Promotion Conference" inHong Kong SAR. Centered on ...
2025-12-24 10:00
2512
Week's Top Stories
Most Reposted
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 269 media titles]
2026-10-01 10:00
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 269 media titles]
2026-09-30 10:50
Sunway University to Host Asia's First Global Tipping Points Conference 2026
[Picked up by 263 media titles]
2026-09-30 12:11
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 261 media titles]
2026-10-02 16:27
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
23617
